Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

After UK Cancelled Order, EU Could Provide Lifeline

 
• By Andrew McConaghie
  
Valneva Livingston
Valneva has lost out on a deal with the UK government worth $1.24bn, and is now looking for other customers for its vaccine. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip